Jafron Biomedical Co.,Ltd. (SHE:300529)

China flag China · Delayed Price · Currency is CNY
22.76
+0.04 (0.18%)
Jul 22, 2025, 2:45 PM CST
-19.89%
Market Cap17.59B
Revenue (ttm)2.48B
Net Income (ttm)724.21M
Shares Out774.36M
EPS (ttm)0.93
PE Ratio24.51
Forward PEn/a
Dividend0.80 (3.52%)
Ex-Dividend DateMay 26, 2025
Volume6,628,812
Average Volume7,736,255
Open22.61
Previous Close22.72
Day's Range22.57 - 22.94
52-Week Range20.73 - 39.24
Beta0.45
RSI59.51
Earnings DateAug 29, 2025

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. The company provides solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases. It offers HA series hemoperfusion cartridge, BS series bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, disinfectants, hemodialysis co... [Read more]

Sector Healthcare
Founded 1989
Employees 2,797
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300529
Full Company Profile

Financial Performance

In 2024, Jafron Biomedical's revenue was 2.68 billion, an increase of 39.27% compared to the previous year's 1.92 billion. Earnings were 820.20 million, an increase of 87.91%.

Financial Statements

News

There is no news available yet.